Product Images Carmustine

This is a document regarding the use and handling of Carmustine for Injection, a medication that comes with a vial of sterile diluent. The medication needs to be stored in a refrigerator and handled with gloves. After being reconstituted, it should be used immediately but not stored. The vial should be examined for crystals before use and in case crystals are found the vial should be warmed to room temperature and shaken to redissolve them. It also contains information about the manufacturer, dosage and instructions for dilution.*

This is a set of instructions and guidelines for handling Carmustine Carmustine, a drug that requires refrigeration at a specific temperature range. The text advises the reader to wear gloves when handling the drug's containers and discard single-dose vials if unused. Additionally, it describes how to prepare the drug for intravenous infusion, warning to examine the solution for crystal formation and how to redissolve them. The recommended dosage information is not included in the text. The manufacturer's name and location are also mentioned.*

This is a pharmaceutical product represented by NDC 16729-544-85. It is for Rx only and requires reconstitution of 1.5 mL Garmustine with the Sterile Diluent for Carmustine as manufactured by Accord Healthcare Inc. The product should be stored in a refrigerator at 2°C to 8°C. The Expiry date is available but not readable.*

This is a set of instructions and precautions for handling and storing Carmustine for injection, USP. The drug should be kept refrigerated at a specific temperature range and diluted immediately after reconstitution. Gloves should be worn when handling the containers. It is important to check for crystal formation before use and redissolve if necessary. The drug should be protected from light and unused portions of the single-dose vial should be discarded. The manufacturing company and product details are provided, but the text does not specify the medical application of this drug.*

This is a prescription medication with the NDC code 16729-547-19. It is an injection, USP that should be stored in a refrigerator between 2°C and 8°C (36°F to 46°F). This injection is manufactured by Accord Healthcare, Inc., in Durham, NC. It comes with sterile diluent for Carmustine, which is manufactured by Intas Pharmaceuticals Limited in Ahmedabad, India. The expiry date is not provided.*

These are instructions for using the Product Kit Guard for Carmustine for Injection, an approved drug that helps to treat certain types of cancer. The Product Kit Guard should be kept in its carton until use and has two compartments – one holds the 300 mg carmustine vial, and the other holds a 9 mL sterile diluent vial. Wear gloves when handling the guard, and discard it after use. To use, remove the flip seals from both vials, and inject the diluent into the carmustine vial aseptically using a sterile syringe. Thereafter, aseptically add 81 mL of sterile water for injection, shake the mixture, and then add a further dilution as recommended. The Product Kit Guard should always be held firmly using a hand while handling. If you require more information, you can contact Accord Healthcare, the manufacturer of the kit.*

These are instructions for using the Product Kit Guard for Carmustine for Injection. The kit should be kept in its carton until the time of use and the vials should not be removed. The kit has two compartments for the carmustine vial and the 3 mL sterile diluent vial. Gloves must be worn when handling the kit and discarded after use. The instructions detail the steps for removing the Flip seals from both vials, aseptically removing 1.5 mL sterile diluent from the vial with the help of sterile syringe, and injecting the 1.5 mL of sterile diluent into the vial containing 50 mg carmustine. The diluted product is then infused after further dilution as recommended with 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. For more information, contact Accord Healthcare Inc. at 1-866-941-7875. The product is manufactured by Intas Pharmaceuticals Limited in Gujarat, India, and is approved until May 2022.*